Unlocking the Next Generation of Therapies with srRNA by Combining Molecules, Extending Half-Life, & Improving Tolerability

• Combining multiple molecules can enable new approaches to multi-mechanism treatment
• Extending half-life can move shorter-acting molecules towards longer dosing intervals and potentially monthly dosing
• Improving drug exposure profiles can reduce fluctuations; this could potentially drive improvements to tolerability

Speakers:

Nathaniel Wang

Co-Founder & CEO

Replicate Bioscience